Brief: Inhibikase Therapeutics Reports Full Year 2021 Financial Results
31/03/2022 22:02
March 31 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS FULL YEAR 2021 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS - EXPECTS EXISTING CASH AND CASH
EQUIVALENTS SUFFICIENT TO FUND EXPENDITURE REQUIREMENTS INTO Q3
OF 2023
Source text for Eikon: ID:nPnbj61yna
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share